142 related articles for article (PubMed ID: 38190969)
41. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
42. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
43. Predicting the Likelihood of Carrying a
Ang BH; Ho WK; Wijaya E; Kwan PY; Ng PS; Yoon SY; Hasan SN; Lim JMC; Hassan T; Tai MC; Allen J; Lee A; Taib NAM; Yip CH; Hartman M; Lim SH; Tan EY; Tan BKT; Tan SM; Tan VKM; Ho PJ; Khng AJ; Dunning AM; Li J; Easton DF; Antoniou AC; Teo SH
J Clin Oncol; 2022 May; 40(14):1542-1551. PubMed ID: 35143328
[TBL] [Abstract][Full Text] [Related]
44. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
45. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
46. BRCA mutations in the management of breast cancer: the state of the art.
Narod SA
Nat Rev Clin Oncol; 2010 Dec; 7(12):702-7. PubMed ID: 20956982
[TBL] [Abstract][Full Text] [Related]
47. Screening for familial cancer risk: Focus on breast cancer.
Rousset-Jablonski C; Gompel A
Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315
[TBL] [Abstract][Full Text] [Related]
48. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
49. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
50. [PALB2, a major susceptibility gene for breast cancer].
Piffer A; Luporsi E; Mathelin C
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
[TBL] [Abstract][Full Text] [Related]
51. Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Lattimore V; Parsons MT; Spurdle AB; Pearson J; Lehnert K; Sullivan J; Lintott C; Bawden S; Morrin H; Robinson B; Walker L
Breast Cancer Res Treat; 2021 Feb; 185(3):583-590. PubMed ID: 33113089
[TBL] [Abstract][Full Text] [Related]
52. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Chang J; Elledge RM
Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
[TBL] [Abstract][Full Text] [Related]
53. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
[TBL] [Abstract][Full Text] [Related]
54. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
Metcalfe KA; Gronwald J; Tung NM; McCuaig JM; Eisen A; Elser C; Foulkes WD; Neuhausen SL; Senter L; Moller P; Bordeleau L; Fruscio R; Velsher L; Zakalik D; Olopade OI; Eng C; Pal T; Cullinane CA; Couch FJ; Kotsopoulos J; Sun P; Lubinski J; Narod SA
Cancer; 2023 Mar; 129(6):901-907. PubMed ID: 36571512
[TBL] [Abstract][Full Text] [Related]
55. [Multidisciplinary team meetings settings on the management of women at high risk of inherited breast cancer. A French study].
Gillmann F; Cordier C; Taris N; Mathelin C; Maugard CM
Bull Cancer; 2016 Jun; 103(6):571-83. PubMed ID: 27178881
[TBL] [Abstract][Full Text] [Related]
56. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
57. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
58. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
[TBL] [Abstract][Full Text] [Related]
59. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
60. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
